MVASI™ is a vascular endothelial growth factor inhibitor indicated for the treatment of: MVASI™, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer... Read More
Metastatic colorectal cancer
Non-squamous non-small cell lung cancer
Recurrent glioblastoma
Metastatic renal cell carcinoma
Cervical cancer
FOLFOX4 = 5-fluorouracil, leucovorin, and oxaliplatin; IFL = irinotecan, fluorouracil, and leucovorin; Q2W = once every 2 weeks; Q3W = once every 3 weeks.
AVAILABLE IN
100 AND 400 MG
SINGLE-DOSE VIALS,
ADMINISTERED BY
INTRAVENOUS
INFUSION1
MVASI™ has an established
Q-code:
Q5107
MVASI™ HAS THE SAME DOSING AND ADMINISTRATION AS AVASTIN®1,2
Pregnancy warning
Most common adverse events
Indication-specific adverse events
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Prescribing Information for additional Important Safety Information.
MVASI™ Indications
MVASI™ is a vascular endothelial growth factor inhibitor indicated for the treatment of:
MVASI™, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer.
MVASI™, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab product-containing regimen.
Limitations of Use: MVASI™ is not indicated for adjuvant treatment of colon cancer.
MVASI™, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer.
MVASI™ is indicated for the treatment of recurrent glioblastoma in adults.
MVASI™, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma.
MVASI™, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
Avastin® (bevacizumab) is a registered trademark of Genentech USA, Inc.
MVASI™ Important Safety Information
References: 1. MVASI™ (bevacizumab-awwb) Prescribing Information, Amgen. 2. Avastin® (bevacizumab) Prescribing Information, Genentech USA, Inc. 3. Data on file, Amgen; 2018. 4. Data on file, Amgen; 2019.